Press "Enter" to skip to content

Pre-clinical findings indicate UV-A light device eradicates viruses and bacteria

In a prospectus supplement dated June 4, 2021, filed with the US Securities and Exchange Commission, Aytu BioPharma, Inc. (NASDAQ: AYTU), disclosed that the Company’s clinical-stage medical device asset, an ultraviolet (UV)-A light endotracheal catheter referred to as Healight™, is being studied as a potential treatment for mechanically ventilated patients suffering from severe respiratory infections, including the infection caused by SARS-CoV-2 (the virus implicated in COVID-19). In April 2020, Aytu BioPharma licensed global rights to the Healight technology platform from Cedars-Sinai Medical Center. The research team at the Medically Associated Science and Technology (“MAST”) Program at Cedars-Sinai has been…
This content is viewable by members only. Visit MY ACCOUNT on the top menu to log in or to register for a 30 day free trial or purchase a subscription for UV Reporter 1 Year Single Membership or UV Reporter 1 Year Group Membership - $189 for first member and $25 for each additional member.